Abstract
Objective Mitral valve prolapse (MVP) is a common cardiac valve disease, which affects 1 in 40 in the general population. Previous GWAS have identified six risk loci for MVP. But these loci explained only partially the genetic risk for MVP. We aim to identify additional risk loci for MVP by adding a dataset from the UK Biobank.
Approaches and Results We re-analyzed 1,007/1,469 cases and 479/862 controls from the MVP-France study and the MVP-Nantes study, respectively. We re-imputed genotypes using HRC and TOPMed, and found this latter to perform better in terms of accuracy in the lower ranges of minor allele frequency (MAF) below 0.1. We then incorporated 434 MVP cases and 4,527 controls from the UKBiobank and conducted a meta-analysis GWAS including ∼2000 MVP cases and over 6,800 controls for ∼8 million genotyped or imputed common SNPs (MAF>0.01). We replicated the association on chr2 and now provide a finer association map near TNS1. We identified three suggestive risk loci, all driven by common variants on Chr1 (SYT2), Chr8 (MSRA), and Chr19 (FBXO46). Gene-based association using MAGMA revealed 15 risk genes for MVP including GLIS1, TGFB2, ID2, TBX5, MSRA, and DMPK. Extensive functional annotation showed that genes associated with MVP are highly expressed in cardiovascular tissues, especially heart, and are involved in cardiac development and potentially aging.
Conclusions We report an updated meta-analysis GWAS for MVP using dense imputation coverage and an improved case-control sample. We describe several loci and genes with MVP spanning biological mechanisms highly relevant to MVP, especially during valve and heart development.
TOC category - basic and population studies
TOC subcategory - Arteriosclerosis, Thrombosis, and Vascular Biology
Highlights
Provide high coverage meta-analysis of GWAS based on TOPMed imputation involving ∼8 million common variants in ∼2000 MVP patients and ∼6800 controls.
Low frequency variant contributed little to the association of the genes mentioned, where the associations were driven by common variants
Several association loci involve genes related to cardiac development and potentially aging.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by a Ph.D. scholarship from the China Scholarship Council to MY, and French Agency of Research (ANR-16-CE17-0015-02). AG, SK, and NB-N are supported by a European Research Council grant (ERC-Stg-ROSALIND-716628). The recruitment of the MVP France cohort was supported by the French Society of Cardiology (SFC). The recruitment of the MVP Nantes cohort was supported by Federation Francaise de Cardiologie, Fondation Coeur et Recherche, French Ministry of Health (PHRC-I 2012), and INSERM Translational Research Grant. The genotyping of the controls from the Three-City Study (3C) was supported by the non-profit organization Fondation Alzheimer (Paris, France). This work was supported in part by grants from the National Institutes of Health (GM103444 to RAN; R01HL131546, RO1HL149696, P20GM103444, and R01HL127692 to RAN; and American Heart Association (19TPA34850095 to RAN, 17CSA33590067 to RAN)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approvals for MVP-France were obtained from CPP Ile-de-France VI, (approval number 60-08, June 25th, 2008), the Commission Informatique et Libertes (CNIL) (approval number 908359, October 14th, 2008) and the French Ministry of Health (ID-RCB: 2008-A00568-47) and was registered on the ClinicalTrial.Gov website (protocol ID: 2008-01). The MVP-Nantes study complies with the Declaration of Helsinki, the French guidelines for genetic research, and was approved by local ethics committees. Written informed consent was obtained. The ethics research committee reference for UK Biobank is 11-NW-0382.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Abbreviations
- MVP
- Mitral Valve Prolapse
- HRC
- Haplotype Reference Consortium
- TOPMed
- Trans-Omics for Precision Medicine
- SNP
- Single Nucleotide Polymorphism
- GWAS
- Genome-Wide Association Study
- eQTLs
- Expression Quantitative Trait Locus
- MAF
- Minor allele frequency
- RA
- Risk Allele
- OR
- Odds Ratio
- CI
- Confidence Interval
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos